Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Read more here.

The program halts will shrink Recursion’s pipeline to six active programs—four in cancer and two in rare diseases.

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...

Recursion uses a data-driven approach to drug discovery, launching four clinical trials in 2021 and planning a fifth in oncology. Click here to read more.

We recently published a list of 10 Stocks Are Dominating Like Wall Street Titans. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against ...

Rallybio (NASDAQ:RLYB) shares climbed ~114% in the premarket on Tuesday after the company announced an agreement to sell its ...

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbioSALT LAKE CITY, Nov. 09, 2023 ...

You must be comfortable with Python programming. This includes basic control structures in Python: conditional branches, for loops and recursion; functions: defining and calling functions, and ...

With a technique called cell painting, Recursion Pharmaceuticals is creating a really big picture of morphology of cells in the body. But that's just the beginning; the really hard part is knowing ...

“We are thrilled to announce that Recursion is setting a new gold standard for the industry with the release of OpenPhenom-S/16, a foundation model for microscopy data trained using masked ...